News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sucampo Pharmaceuticals, Inc. (SCMP) Announces Japanese Government Funding for Unoprostone Isopropyl Development in Retinitis Pigmentosa



2/4/2013 10:16:14 AM

BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that the Japan Science and Technology Agency (JST) has adopted unoprostone isopropyl ophthalmic solution .15% in the Adaptable and Seamless Technology Transfer Program. As part of this program, R-Tech Ueno, Sucampo’s development partner, has signed an agreement for unoprostone isopropyl with the JST in which the Japanese government shall provide the majority of funding* for Phase 3 clinical development costs for unoprostone isopropyl for retinitis pigmentosa (RP). Sucampo is co-developing unoprostone isopropyl with R-Tech Ueno and may file for FDA approval of the product for retinitis pigmentosa (RP) in the future assuming the successful trials.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES